Belimumab

Where the papers sit

12 papers from the last 6 months study belimumab directly · updated from PubMed 6 Oct 2026

• Refractory Lupus and Nephritis

  Belimumab is being used for refractory systemic lupus erythematosus, with particular attention to lupus nephritis and disease-activity control. Real-world cohorts report reduced activity alongside prednisone use and anti-double-stranded DNA antibody monitoring. Baseline peripheral-blood CD19+ B-cell proportions may help predict early complete response. The role of serological markers is being refined, while renal guideline integration remains an open clinical priority.

  5 papers · 41.7%

• Lupus Organ Manifestation Treatment

  Belimumab is being extended to difficult lupus manifestations, especially thrombocytopenia, leukopenia and other hematological disease. Early and sustained resolution of thrombocytopenia is the clearest recurring treatment signal. Evidence for SLE-associated pulmonary arterial hypertension remains limited to single-centre experience, while neuropsychiatric disease is part of broader response assessment. Better core outcome domains are needed to compare responses across organ systems.

  4 papers · 33.3%

• Lupus Remission and Organ Protection

  Belimumab treatment is moving toward steroid-sparing targets defined by DORIS remission and lupus low disease activity state. Post hoc and real-world analyses suggest benefit over placebo and feasible attainment of adapted remission goals without the glucocorticoid component. Long-term extension data connect sustained treatment with reduced organ damage over eight years and continued safety follow-up to 13 years. Whether these targets consistently translate into durable protection across routine-care populations remains open.

  3 papers · 25%